Scholarlink

Purpose <p>Neoadjuvant chemotherapy (NAC) is considered standard of care for patients with cT2 + and/or N + triple negative (TN) and HER2-positive (HER2 +) breast cancer (BC). A previous retrospective study showed only 23.9% of stage II–III TN or HER2 + BC patients in Ontario received NAC. This study aimed to identify provider-level facilitators and barriers to using NAC as first-line treatment.</p> Methods <p>We surveyed General Surgeons in Ontario using a self-administered questionnaire developed through systematic item generation and reduction. We evaluated face and content validity, as well as test–retest reliability. Surveys were sent via mail delivery with reminder. Participants could also use a QR code to access the online version. Quantitative data were analysed with descriptive statistics and qualitative responses examined using open coding.</p> Results <p>Total response rate was 21.1% (212/1005). All respondents who treated BC (71/71) reported being aware of indications and benefits of NAC for TNBC and HER2 + BC. Most respondents reported recommending NAC for node positive and node negative, &gt; 2&#xa0;cm TNBC (97.2%) and were equally likely for node positive HER2 + (98.6%), but less likely for node negative, &gt; T2 (88.7%). Respondents perceived patient factors (e.g. age and comorbidities and patient’s fear of chemotherapy) as barriers towards receiving NAC. The most reported facilitator to NAC was access to multidisciplinary cancer conferences.</p> Conclusion <p>Surgeons demonstrated strong knowledge of NAC’s indications and benefits, indicating that low NAC rates are likely not due to lack of awareness. Patient factors remain the major barriers to NAC uptake.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Provider level facilitators and barriers towards neoadjuvant chemotherapy for triple negative and HER2 + breast cancer: a survey of Ontario surgeons

  • 期刊论文

  • 发表日期：

    2026年4月17日

查看全文
  • Gary Ko,
  • Elwyn Zhang,
  • Elliott Yee,
  • Julie Hallet,
  • Natalie Coburn,
  • Frances C. Wright,
  • Sonal Gandhi,
  • Katarzyna J. Jerzak,
  • Andrea Eisen,
  • Nicole J. Look Hong,
  • Amanda Roberts

摘要

Purpose

Neoadjuvant chemotherapy (NAC) is considered standard of care for patients with cT2 + and/or N + triple negative (TN) and HER2-positive (HER2 +) breast cancer (BC). A previous retrospective study showed only 23.9% of stage II–III TN or HER2 + BC patients in Ontario received NAC. This study aimed to identify provider-level facilitators and barriers to using NAC as first-line treatment.

Methods

We surveyed General Surgeons in Ontario using a self-administered questionnaire developed through systematic item generation and reduction. We evaluated face and content validity, as well as test–retest reliability. Surveys were sent via mail delivery with reminder. Participants could also use a QR code to access the online version. Quantitative data were analysed with descriptive statistics and qualitative responses examined using open coding.

Results

Total response rate was 21.1% (212/1005). All respondents who treated BC (71/71) reported being aware of indications and benefits of NAC for TNBC and HER2 + BC. Most respondents reported recommending NAC for node positive and node negative, > 2 cm TNBC (97.2%) and were equally likely for node positive HER2 + (98.6%), but less likely for node negative, > T2 (88.7%). Respondents perceived patient factors (e.g. age and comorbidities and patient’s fear of chemotherapy) as barriers towards receiving NAC. The most reported facilitator to NAC was access to multidisciplinary cancer conferences.

Conclusion

Surgeons demonstrated strong knowledge of NAC’s indications and benefits, indicating that low NAC rates are likely not due to lack of awareness. Patient factors remain the major barriers to NAC uptake.